In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater"

MeSH terms

• Antibodies, Monoclonal, Humanized
• B7-H1 Antigen
• Carcinoma, Non-Small-Cell Lung* / drug therapy
• Cost-Benefit Analysis
• Humans
• Lung Neoplasms* / drug therapy